DURECT (DRRX) Competitors $0.85 +0.03 (+3.03%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends DRRX vs. KPTI, OSTX, ME, ORMP, SKYE, IMUX, SCLX, IPSC, ALXO, and ENTXShould you be buying DURECT stock or one of its competitors? The main competitors of DURECT include Karyopharm Therapeutics (KPTI), OS Therapies (OSTX), 23andMe (ME), Oramed Pharmaceuticals (ORMP), Skye Bioscience (SKYE), Immunic (IMUX), Scilex (SCLX), Century Therapeutics (IPSC), ALX Oncology (ALXO), and Entera Bio (ENTX). These companies are all part of the "pharmaceutical products" industry. DURECT vs. Karyopharm Therapeutics OS Therapies 23andMe Oramed Pharmaceuticals Skye Bioscience Immunic Scilex Century Therapeutics ALX Oncology Entera Bio Karyopharm Therapeutics (NASDAQ:KPTI) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends. Which has more risk & volatility, KPTI or DRRX? Karyopharm Therapeutics has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. Comparatively, DURECT has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Which has higher valuation and earnings, KPTI or DRRX? DURECT has lower revenue, but higher earnings than Karyopharm Therapeutics. DURECT is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$148.44M0.54-$143.10M-$1.14-0.56DURECT$8.59M3.07-$27.62M-$0.61-1.39 Do insiders and institutionals hold more shares of KPTI or DRRX? 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 2.8% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 3.2% of DURECT shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is KPTI or DRRX more profitable? Karyopharm Therapeutics has a net margin of -58.93% compared to DURECT's net margin of -198.58%. Karyopharm Therapeutics' return on equity of 0.00% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-58.93% N/A -41.25% DURECT -198.58%-300.62%-65.17% Does the media prefer KPTI or DRRX? In the previous week, Karyopharm Therapeutics had 4 more articles in the media than DURECT. MarketBeat recorded 7 mentions for Karyopharm Therapeutics and 3 mentions for DURECT. DURECT's average media sentiment score of 1.28 beat Karyopharm Therapeutics' score of 0.93 indicating that DURECT is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DURECT 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate KPTI or DRRX? Karyopharm Therapeutics presently has a consensus price target of $5.00, suggesting a potential upside of 689.64%. DURECT has a consensus price target of $5.00, suggesting a potential upside of 488.24%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Karyopharm Therapeutics is more favorable than DURECT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00DURECT 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community prefer KPTI or DRRX? Karyopharm Therapeutics received 219 more outperform votes than DURECT when rated by MarketBeat users. Likewise, 72.20% of users gave Karyopharm Therapeutics an outperform vote while only 62.95% of users gave DURECT an outperform vote. CompanyUnderperformOutperformKaryopharm TherapeuticsOutperform Votes53572.20% Underperform Votes20627.80% DURECTOutperform Votes31662.95% Underperform Votes18637.05% SummaryKaryopharm Therapeutics beats DURECT on 12 of the 18 factors compared between the two stocks. Get DURECT News Delivered to You Automatically Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRRX vs. The Competition Export to ExcelMetricDURECTPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.39M$6.54B$5.25B$8.80BDividend YieldN/A2.91%5.07%4.00%P/E Ratio-1.3910.2186.0516.97Price / Sales3.07201.231,085.58118.05Price / CashN/A57.6743.2137.77Price / Book1.704.885.044.89Net Income-$27.62M$154.38M$122.32M$228.40M7 Day Performance-2.30%-8.12%-4.65%-3.68%1 Month Performance13.33%-3.16%-0.99%0.03%1 Year Performance29.18%-4.63%23.64%13.82% DURECT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRRXDURECT4.1107 of 5 stars$0.85+3.0%$5.00+488.2%+25.4%$26.39M$8.59M-1.3980Analyst ForecastShort Interest ↓News CoveragePositive NewsKPTIKaryopharm Therapeutics4.1131 of 5 stars$0.80+2.7%$5.00+524.2%-9.6%$101.08M$148.44M-0.70380News CoverageOSTXOS TherapiesN/A$4.69+10.1%$8.00+70.6%N/A$99.61MN/A0.00N/AGap UpME23andMe1.4876 of 5 stars$3.79flat$9.40+148.0%-74.3%$98.99M$193.26M-0.15770ORMPOramed Pharmaceuticals2.6341 of 5 stars$2.43-0.4%N/A+0.9%$97.96M$1.34M22.0910Analyst UpgradeShort Interest ↓News CoverageSKYESkye Bioscience1.6838 of 5 stars$3.22+13.0%$18.67+479.7%+0.0%$97.69MN/A0.0011News CoverageIMUXImmunic2.5182 of 5 stars$1.07-2.7%$11.80+1,002.1%-16.4%$96.45MN/A-0.8770Short Interest ↑SCLXScilex3.8049 of 5 stars$0.50+4.7%$11.33+2,181.3%-75.4%$95.28M$50.83M-0.3580News CoverageIPSCCentury Therapeutics2.3652 of 5 stars$1.12+0.9%$10.00+792.9%-74.7%$95.23M$2.68M-0.61170Short Interest ↑Gap UpALXOALX Oncology3.6651 of 5 stars$1.81-0.3%$8.50+370.9%-88.2%$95.20MN/A-0.6140Short Interest ↓ENTXEntera Bio2.9806 of 5 stars$2.63-2.2%$10.00+280.2%+120.2%$94.12M$99,000.00-10.1220Short Interest ↓Positive NewsGap Up Related Companies and Tools Related Companies KPTI Competitors OSTX Competitors ME Competitors ORMP Competitors SKYE Competitors IMUX Competitors SCLX Competitors IPSC Competitors ALXO Competitors ENTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DRRX) was last updated on 1/14/2025 by MarketBeat.com Staff From Our PartnersStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
